In diffuse large B-cell lymphoma (DLBCL), BCL2 expression usually correlates with the t(14;18) (q32;q21) in germinal center B-cell (GCB) subtype and with gain/amplification of chromosome 18q21 in the activated B cell鈥搇ike subtype. Studies have suggested that the GCB subtype is less ...
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. Cell-of-origin classification in DLBCL has identified activated B cell (ABC) and germinal center B cell (GCB) as two major subtypes. Patients with the ABC subtype show reduced overall survival with standard therapies. Development ...
High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy 热度: simultaneous drug targeting of the promoter myc g-quadruplex and bcl2 i-motif in diffuse large b-cell lymphoma delays tumor growth.[2017]...
Laboratory Investigation (2015) 95, 113–120 & 2015 USCAP, Inc All rights reserved 0023-6837/15 Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR Xuemin Xue1,2, Naiyan Zeng2, Zifen Gao1 and Ming-Qing Du2 Diffuse large B-cell lymphoma (DLBCL) is a...
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasi
De novo diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma worldwide, accounting for approximately 30–40% of adult non-Hodgkin lymphomas. It is defined as a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding that of a normal ...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Prognosis is strongly associated with molecular subgroup, although the driver mutations that distinguish the two main subgroups remain poorly defined. Through an integrative analysis of whole genomes, exomes,...
关键词: diffuse large B-cell lymphoma REAL classification ‘diffuse large B-cell lymphoma’ (DLBCL) large-cell lymphomas smaller T lymphocytes EBV-encoded RNA (EBER) anaplastic tumours histiocytic sarcoma Kikuchi necrotising lymphadenitis borderline subtype, CHL ...
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is accepted as the best available standard treatment for diffuse large B-cell lymphoma (DLBCL) patients; however, the therapeutic efficacy seems unsatisfactory. Additional rituximab will improve the cure rate, but it is not popular in Chi...
Diffuse large B cell lymphoma (DLBCL) is an aggressive blood cancer known for its rapid progression and high incidence. The growing use of immunohistochemistry (IHC) has significantly contributed to the detailed cell characterization, thereby playing a crucial role in guiding treatment strategies for ...